top of page

Assessment of epi and genetic and clinical outcomes of resistance to bedaquiline

resisttb
Full title: Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study
On January 20th, 2021 RESIST-TB hosted a webinar to discuss updates on surveillance for resistance to new and repurposed drugs around the world. One of our speakers, Farzana Ismail, has now published their paper “Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to Bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.” Baseline bedaquiline resistance was seen in 3·8% of patients, while resistance developed during treatment in 16% of patients. The article demonstrates the importance of surveillance for resistance to the new drugs. Read Here.
3 views0 comments

Recent Posts

See All

Armand Van Deun Scholarship Initiative

The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...

Comments


bottom of page